BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11929749)

  • 1. The Stat5-RARalpha fusion protein represses transcription and differentiation through interaction with a corepressor complex.
    Maurer AB; Wichmann C; Gross A; Kunkel H; Heinzel T; Ruthardt M; Groner B; Grez M
    Blood; 2002 Apr; 99(8):2647-52. PubMed ID: 11929749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways.
    Dong S; Tweardy DJ
    Blood; 2002 Apr; 99(8):2637-46. PubMed ID: 11929748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
    Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
    Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TBLR1 fuses to retinoid acid receptor α in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia.
    Chen Y; Li S; Zhou C; Li C; Ru K; Rao Q; Xing H; Tian Z; Tang K; Mi Y; Wang B; Wang M; Wang J
    Blood; 2014 Aug; 124(6):936-45. PubMed ID: 24782508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha.
    Cheng GX; Zhu XH; Men XQ; Wang L; Huang QH; Jin XL; Xiong SM; Zhu J; Guo WM; Chen JQ; Xu SF; So E; Chan LC; Waxman S; Zelent A; Chen GQ; Dong S; Liu JX; Chen SJ
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6318-23. PubMed ID: 10339585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia.
    Hong SH; David G; Wong CW; Dejean A; Privalsky ML
    Proc Natl Acad Sci U S A; 1997 Aug; 94(17):9028-33. PubMed ID: 9256429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
    Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
    Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translocations of the RARalpha gene in acute promyelocytic leukemia.
    Zelent A; Guidez F; Melnick A; Waxman S; Licht JD
    Oncogene; 2001 Oct; 20(49):7186-203. PubMed ID: 11704847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers.
    Lin RJ; Evans RM
    Mol Cell; 2000 May; 5(5):821-30. PubMed ID: 10882118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusion protein of retinoic acid receptor alpha with promyelocytic leukemia protein or promyelocytic leukemia zinc finger protein recruits N-CoR-TBLR1 corepressor complex to repress transcription in vivo.
    Tomita A; Buchholz DR; Obata K; Shi YB
    J Biol Chem; 2003 Aug; 278(33):30788-95. PubMed ID: 12794076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of SMRTbeta promotes ligand-induced activation of mutated and wild-type retinoid receptors.
    Côté S; McNamara S; Brambilla D; Bianchini A; Rizzo G; del Rincón SV; Grignani F; Nervi C; Miller WH
    Blood; 2004 Dec; 104(13):4226-35. PubMed ID: 15319284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional interaction of STAT5 and nuclear receptor co-repressor SMRT: implications in negative regulation of STAT5-dependent transcription.
    Nakajima H; Brindle PK; Handa M; Ihle JN
    EMBO J; 2001 Dec; 20(23):6836-44. PubMed ID: 11726519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells.
    Racanicchi S; Maccherani C; Liberatore C; Billi M; Gelmetti V; Panigada M; Rizzo G; Nervi C; Grignani F
    EMBO J; 2005 Mar; 24(6):1232-42. PubMed ID: 15729358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression.
    Xu K; Guidez F; Glasow A; Chung D; Petrie K; Stegmaier K; Wang KK; Zhang J; Jing Y; Zelent A; Waxman S
    Cancer Res; 2005 Sep; 65(17):7856-65. PubMed ID: 16140955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemia.
    Hong SH; Yang Z; Privalsky ML
    Mol Cell Biol; 2001 Nov; 21(21):7172-82. PubMed ID: 11585900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins.
    Zhong S; Delva L; Rachez C; Cenciarelli C; Gandini D; Zhang H; Kalantry S; Freedman LP; Pandolfi PP
    Nat Genet; 1999 Nov; 23(3):287-95. PubMed ID: 10610177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The transcriptional corepressor CBFA2T3 inhibits all-
    Steinauer N; Guo C; Zhang J
    J Biol Chem; 2020 Jul; 295(27):8887-8900. PubMed ID: 32434928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6.
    Wong CW; Privalsky ML
    J Biol Chem; 1998 Oct; 273(42):27695-702. PubMed ID: 9765306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
    Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
    Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of differential binding of wild-type RARalpha, PML-, PLZF- and NPM-RARalpha fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia.
    So CW; Dong S; So CK; Cheng GX; Huang QH; Chen SJ; Chan LC
    Leukemia; 2000 Jan; 14(1):77-83. PubMed ID: 10637480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.